All In Biotech

Drug Trial Radar · NCT05768854

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

69

Actual

Start

Jun 14, 2023

Primary completion

Oct 23, 2025

Study completion Apr 2027

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the effect of setrusumab vs intravenous bisphosphonates (IV-BP) on reduction in fracture rate, including morphometric vertebral fractures in pediatric participants.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • BisphosphonateDrug

    Administered per investigator discretion via intravenous (IV) infusion

  • SetrusumabBiological

    A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures, at the Primary AnalysisTime frame: Up to 24 Months

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Childrens Hospital LA

    Los Angeles, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Nemours/ Alfred i. duPoint Hospital for Children

    Wilmington, Delaware

  • Children's National Hospital DC

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • Shriners Hospitals for Children Chicago

    Chicago, Illinois

  • Washington University School of Medicine

    St Louis, Missouri

  • University of North Carolina at Chapel Hill (UNC)

    Chapel Hill, North Carolina

  • Vanderbilt University Medical Center (VUMC)

    Nashville, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Hospital de Clinicas de Porto Alegre (HCPA)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Childrens Hospital Of Eastern Ontario Research Institute, University Of Ottawa

    Ottawa, Canada

  • Children's Hospital at London Health Sciences Centre

    London, Ontario, Canada

  • Institut Imagine

    Paris, France

  • Azienda Ospedaliera Universitaria Policlinico Umberto I

    Roma, Italy

  • Universitair Medisch Centrum Utrecht (UMCU) - Wilhelmina Kinderziekenhuis

    Utrecht, Netherlands

  • Uniwersytet Medyczny w Lodzi - Klinika Endokrynologii i Chorob Metabolicznych

    Lodz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.